Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 10/05 cls
Adventrx (ANX) Fortis David Garrett Downgrade Hold (from buy) -70% $0.78
Garrett lowered his target to $0.50 from $6 after CoFactor (ANX-510), a folate-based active metabolite of leucovorin, missed the primary endpoint in a Phase IIb trial to treat metastatic colorectal cancer. He believes the prospects for success in the ongoing Phase III trial are greatly diminished (see B16).
Aeterna (TSX:AEL; AELA) Rodman Ren Benjamin Price target

Read the full 847 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers